Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > FDA extends review period for Aducanumab
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Mole101on Jan 29, 2021 1:48pm
114 Views
Post# 32421658

RE:RE:FDA extends review period for Aducanumab

RE:RE:FDA extends review period for AducanumabInteresting day in the markets, I wander if that news has something to do with PMN activity today ?...

House  Bought  Sold  Net 
House 001
Anonymous
Bought $14,065
Volume 147,600
Average $0.095
Sold $17,017
Volume 177,500
Average $0.096
Net $-2,952
Volume -29,900
 
House 002
RBC
Bought $21,076
Volume 220,500
Average $0.096
Sold $11,885
Volume 125,900
Average $0.094
Net $9,191
Volume 94,600
 
House 007
TD Sec
Bought $22,730
Volume 231,741
Average $0.098
Sold $5,175
Volume 51,821
Average $0.100
Net $17,555
Volume 179,920
 
House 009
BMO Nesbitt
Bought 0
Volume 0
Average 0
Sold $12,000
Volume 120,000
Average $0.100
Net $-12,000
Volume -120,000
 
House 013
Instinet
Bought $6,650
Volume 70,000
Average $0.095
Sold 0
Volume 0
Average 0
Net $6,650
Volume 70,000
 
House 019
Desjardins
Bought 0
Volume 0
Average 0
Sold $47
Volume 500
Average $0.094
Net $-47
Volume -500
 
House 033
Canaccord
Bought $2,185
Volume 23,000
Average $0.095
Sold $42,287
Volume 444,041
Average $0.095
Net $-40,102
Volume -421,041
 
House 036
Latimer
Bought $47
Volume 500
Average $0.094
Sold 0
Volume 0
Average 0
Net $47
Volume 500
 
House 053
Morgan Stanley
Bought 0
Volume 0
Average 0
Sold $500
Volume 5,000
Average $0.100
Net $-500
Volume -5,000
 
House 079
CIBC
Bought $17,900
Volume 184,000
Average $0.097
Sold $900
Volume 9,000
Average $0.100
Net $17,000
Volume 175,000
 
House 080
National Bank
Bought $100
Volume 1,000
Average $0.100
Sold 0
Volume 0
Average 0
Net $100
Volume 1,000
 
House 083
Mackie
Bought $10,670
Volume 112,000
Average $0.095
Sold $6,880
Volume 69,000
Average $0.100
Net $3,790
Volume 43,000
 
House 085
Scotia
Bought $624
Volume 6,000
Average $0.104
Sold $100
Volume 1,000
Average $0.100
Net $524
Volume 5,000
 
House 088
Credential
Bought $129
Volume 1,321
Average $0.098
Sold 0
Volume 0
Average 0
Net $129
Volume 1,321
 
House 124
Questrade
Bought $615
Volume 6,100
Average $0.101
Sold 0
Volume 0
Average 0
Net $615
Volume 6,100
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested